Michael Lyle
Director Técnico/Científico/I+D en Welichem Biotech, Inc. .
Perfil
Michael Lyle is currently the Vice President of Research & Development at Welichem Biotech, Inc. He obtained a doctorate degree from Simon Fraser University.
Cargos activos de Michael Lyle
| Empresas | Cargo | Inicio |
|---|---|---|
Welichem Biotech, Inc.
 Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Director Técnico/Científico/I+D | 01/12/2009 |
Formación de Michael Lyle.
| Simon Fraser University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Lyle
